Clinical Trial Search

Primary: Assess Efficacy of Oral FMT on Composition and Function of the Gut Microbiota Compared to Placebo.

Primary: % Change From Baseline in Total IgE — -45.57 percentage change

Primary: % of Subjects With Successful Preparation Rated by Colonoscopist on a 4 Point Scale (1=Poor to 4 = Excellent) — 13; 10 Participants — p=0.923

Primary: Rate of Grade 3 or Higher Neutropenia — 10 Participants

Primary: Percent of Participants With Clinically Important Change in Drug-induced Liver Injury — 1.0; 0.5; 0 percentage of participants — p== 0.1241

Primary: Population Pharmacokinetics: V - Volume — 0.6572 l/kg

Primary: Change in Breast Density at 6 Months — -5.45; -13.71 cm^3

Primary: Number of Participants With Treatment-Related Grade 3 or 4 Adverse Events as Assessed by CTCAE V4.0 — 2 Participants

Primary: Change From Baseline in Abdominal Pain at Its Worst on a NRS Through the Treatment Period — -2.01; -1.93; -1.58; -1.95 units on a scale — p=0.7467

Primary: The Percentage of Insulin-independent Patients Following Single Infusion Islet Cell Transplantation at Day 75 +/- 5 — 0; 0 percentage of patients

Primary: Change From Baseline in the Percentage of "On" Time Without Dyskinesia Averaged Over Days 1 and 2 in Participants Treated With SUN N4057 and Those Treated With a Placebo…

Primary: Response Rates — 4; 0; 0; 0 Participants

Primary: Number of Participants With an Objective Response — 1; 0; 0; 0 Participants

Primary: Progression-free Survival — 424 days

Primary: Safety: Alanine Transaminase (ALT) — -0.83; -3.27 U/L — p=0.3654